Canada news from FierceBiotech
News
Canada short on biotech workers
Canada's biotech sector is growing, but the country is struggling to find enough "job-ready" candidates. That's according to a new report from BioTalent Canada, which finds that the country is having Read more...
Canada to team with California on stem cells
Canada is giving about $98 million to the Canadian Cancer Stem Cell Consortium so that the country's stem cell scientists can work in tandem with the California Institute for Regenerative Medicine. Read more...
IRX Therapeutics raises $25M Series A
New York-based IRX Therapeutics announced that it has raised $25 million in a Series A. The new money will be used to further develop IRX's cancer and viral disease product platform, including IRX-2 Read more...
Migenix cuts costs to stretch cash
Canada's Migenix is cutting its staff in an effort to preserve cash. The company, which is developing the anti-infective drug Omigard, cut six workers, reduced its CEO's salary and downsized its Read more...
Canadian biotech may face funding crisis
Every country's biotech industry is different. And E&Y's report notes that Canada in particular is "facing a real funding crisis," says Rod Budd, Ernst & Young's Canadian biotech industry Read more...
SPOTLIGHT: Mystery Mistral merger is off
Canada's Mistral Pharma says its proposed merger with an unnamed U.S. specialty pharma company will not be completed. As a result, its bridge financing deal has been canceled and management has Read more...
Sanofi Pasteur plans C$100M R&D facility in Canada
Score one win for Ontario province in the field of economic development. Sanofi Pasteur, the vaccine arm of Sanofi-Aventis, will build a C$100 million R&D facility in Toronto with the province Read more...
SPOTLIGHT: India to convert sites into drug labs
After shuttering three of its oldest vaccine manufacturing facilities for failing to abide by good manufacturing practices, Indian officials have named an expert panel to convert the plants into Read more...
Labopharm 'encouraged' by FDA's stance on Tramadol
Canada's Labopharm says that the FDA did not reverse its decision regarding an approvable letter for once-daily Tramadol, but it noted an encouraging new approach to a statistical method being used Read more...
YM shares hit on clinical trial hold
Canada's YM BioSciences saw its stock take a nasty hit after it announced that the FDA had put a mid-stage trial of its AeroLEF pain therapy on hold as it seeks safety data on volunteers in earlier Read more...
Get more Canada coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends